Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...